Researchers are excited to announce they have started clinical trials to develop a protective vaccine against HIV. This is a huge milestone for the EAVI2020 project and is the first clinical trial to assess how different protein combinations influence the development of protective antibodies. The first dose was administered on March 28 at NIHR Imperial CRF, Hammersmith Hospital, London, with another 50 participants to take part over a 12-month period. Read More
